|
India News Releases
|
(India.CityRegions.Com, October 04, 2017 ) ReportsWeb.com published “Tyrosine Protein Kinase Receptor UFO - Pipeline Review H1 2017” from its database. The report reviews top companies involved and enlists all trials pertaining to the company. Report provides latest news for the past three months. Original Content: According to the recently published report 'Tyrosine Protein Kinase Receptor UFO - Pipeline Review, H1 2017'; Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) pipeline Target constitutes close to 24 molecules. Out of which approximately 23 molecules are developed by companies and remaining by the universities/institutes. For more information about this report: http://www.reportsweb.com/tyrosine-protein-kinase-receptor-ufo-pipeline-review-h1-2017 Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Tyrosine-protein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropin-releasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Toll-like receptors (TLRs) -mediated innate immune response. Report Scope - The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects - The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001834415/sample Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope List of Tables
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indications, H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017 Number of Products under Development by Indications, H1 2017 (Contd..2) , H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1) , H1 2017 Products under Development by Companies, H1 2017 (Contd..2) , H1 2017 Products under Development by Companies, H1 2017 (Contd..3) , H1 2017 Products under Development by Companies, H1 2017 (Contd..4) , H1 2017 Products under Development by Companies, H1 2017 (Contd..5) , H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Astellas Pharma Inc, H1 2017 Pipeline by BerGenBio ASA, H1 2017 Pipeline by Betta Pharmaceuticals Co Ltd, H1 2017 Pipeline by Celldex Therapeutics Inc, H1 2017 ipeline by Exelixis Inc, H1 2017 Pipeline by Ignyta Inc, H1 2017 Pipeline by Les Laboratoires Servier SAS, H1 2017 Pipeline by Mirati Therapeutics Inc, H1 2017 Pipeline by Ono Pharmaceutical Co Ltd, H1 2017 Pipeline by Oribase Pharma, H1 2017 Pipeline by Qurient Co Ltd, H1 2017 Pipeline by SignalChem Lifesciences Corp, H1 2017 Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017 Pipeline by Tolero Pharmaceuticals Inc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1) , H1 2017 Discontinued Products, H1 2017
List of Figures
Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Top 10 Indications, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Routes of Administration, H1 2017 Number of Products by Molecule Types, H1 2017 Number of Products by Stage and Molecule Types, H1 2017 Inquire before Buying at http://www.reportsweb.com/buy&RW0001834415/buy/3500 Contact Us: Call: +1-646-491-9876 Email: sales@reportsweb.com About ReportsWeb: ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
ReportsWeb.com
Rajat Sahni
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com
|
|
|
India RSS Feed Marketpalce
|
India News Headlines
Daily news from India: arts, business, culture, politics, science, technology & more.
Free Sales & Marketing Magazines
Get free publications about marketing, sales and customer relations management.
Submit RSS feed on India. Have your feed on news, products or services displayed under this marketpalce and have your feed on a full page updated daily.
|
|
India Business News by Major Cities
|
|
|
Listen to GroupWeb Radio
INDIA BUSINESS TV
|